Log In
BCIQ
Print this Print this
 

epratuzumab-SN-38

  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionHumanized mAb targeting CD22 conjugated with SN-38, the active metabolite of irinotecan
Molecular Target CD22
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLymphoma
Indication DetailsTreat lymphoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today